Who owns Theravance Biopharma, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Newtyn Management, LLC: 6.7% · 3,434,191 shares — Newtyn TE Partners, LP: 4.3% · 2,212,712 shares
Madison Avenue International LP: 17.7% · 9,212,252 shares — Madison Avenue Partners, LP: 17.7% · 9,212,252 shares — EMAI Management, LLC: 17.7% · 9,212,252 shares
2 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Theravance Biopharma, Inc..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Theravance Biopharma, Inc. they hold. Together these 239 managers report 106.45% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | $157M | 9,212,252 | 6.74% | 17.74% | June 30, 2026 |
| Weiss Asset Management LP | $127M | 7,457,060 | 1.33% | 14.36% | June 30, 2026 |
237 more institutional holders behind a free account
See every manager reporting Theravance Biopharma, Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 74 funds hold 7.33% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | $22M | 0.00% | 2.50% | June 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND | $7.41M | 0.01% | 0.84% | June 30, 2026 |
72 more funds behind a free account
See every fund holding Theravance Biopharma, Inc. and what share of its net assets the position represents.
Sign up freeLoading...
